D.E. Shaw & Co
MRNS

D.E. Shaw & Co’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

D.E. Shaw & Co’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50,000
Closed -$403K – 4701
2023
Q3 		$403K Buy
+50,000
New +$416K ﹤0.01% 3507

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co's MRNS Position: Q4 2024 in Review

D.E. Shaw & Co sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 178,801 shares — an estimated $315K sold.

D.E. Shaw & Co first reported a position in MRNS in Q2 2019 and held it in 7 quarters. The position peaked at $3.85M in Q2 2023. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • D.E. Shaw & Co reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 178,801 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $315K.
  • D.E. Shaw & Co first reported a position in Marinus Pharmaceuticals, Inc in Q2 2019 and held it in 7 quarters.
  • D.E. Shaw & Co's Marinus Pharmaceuticals, Inc position peaked at $3.85M in Q2 2023.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.